parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.01 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced in astrocytes (363 nCPM)	1.00
chemistry Open Targets	reachable by antibody	0.45
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	1 Parkinson's papers of 48	0.91
pathways Reactome	1 pathway; mostly other	0.30

No case: the score is under the bar. Receipt 10244

ACSBG1 in astrocytes, braak-0.37 (p 0.329) → -0.07 (p 0.849)receipt 10252
ACSBG1 in dopamine neurons, braak-0.30 (p 0.428) → -0.76 (p 0.017)receipt 10253

receipt 10253: ACSBG1 in dopamine neurons, braak

power: full sample -0.52 (p 0.026, n 18), 95% CI -0.80 to -0.07. the interval excludes zero: something may be there, smaller than a half can see.
confounder: adjusted for sex: -0.54 (p 0.021, n 18). holds up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.64 (p 0.0039, n 18). not the mix.
skeptic: leave-one-out range -0.66 to -0.46, sign flips 0; without severely affected donors -0.52 (p 0.026, n 18). robust.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for ACSBG1 in dopamine neurons.

case closed: nothing better to follow up.

receipt 10252: ACSBG1 in astrocytes, braak

power: full sample -0.29 (p 0.243, n 18), 95% CI -0.67 to +0.20. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.30 (p 0.221, n 18). does not hold up.
composition: astrocytes share of nuclei vs axis -0.21 (p 0.413); controlling for it: -0.24 (p 0.328, n 18). could be the mix.
skeptic: leave-one-out range -0.39 to -0.20, sign flips 0; without severely affected donors -0.29 (p 0.243, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for ACSBG1 in astrocytes.

case closed: nothing better to follow up.

loading the receipts